Cephalon and Mylan Strike Deal Over Generic Provigil
Posted on: Wednesday, 11 January 2006, 15:00 CST
Cephalon has settled its impending patent dispute with Mylan Pharmaceuticals over Mylan's generic version of the narcolepsy drug Provigil.
Cephalon will grant Mylan a non-exclusive royalty-bearing right to market and sell a generic version of Provigil in the US from October 2011, unless Cephalon obtains a pediatric extension for the drug which would delay entry by Mylan until April 2012.
Mylan may launch its generic version of the drug earlier than October 2011 in the event of another company releasing a generic version of the sleep disorder medicine. The financial terms of the deal were not disclosed.
The parties will now file a dismissal with the United States District Court for the District of New Jersey that will conclude all pending litigation between them regarding Provigil.
Cephalon previously struck similar deals relating to generic versions of the drug made by Teva Pharmaceutical's and Ranbaxy Laboratories.
Source: Datamonitor
Related Articles
- Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
- Mylan's Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
- Cephalon Sleep Drug Requires Warning Label
- Synovics Pharmaceuticals Initiates U.S. Development of Its Third Generic Oral Controlled-Release Drug
- US FDA delays decision on Cephalon ADHD drug
- US FDA OKs generic for popular cholesterol drug
- Cephalon: Experimental Drug Did Not Cause Serious Skin Rash
- Cephalon ADHD Drug Effective but Not Safe: Panel
- Cephalon ADHD Drug to Have Warning: FDA Official
- Generic of GSK Smoking Drug Approved By FDA
 |
 |
User Comments (0)
RSS Feeds